This article has Open Peer Review reports available.
Constitutive RB1 mutation in a child conceived by in vitrofertilization: implications for genetic counseling
© Barbosa et al; licensee BioMed Central Ltd. 2009
Received: 26 February 2009
Accepted: 29 July 2009
Published: 29 July 2009
The purpose of this study was to identify mutations associated with bilateral retinoblastoma in a quadruplet conceived by in vitro fertilization, and to trace the parental origin of mutations in the four quadruplets and their father.
Mutational screening was carried out by sequencing. Genotyping was carried out for determining quadruplet zygosity.
The proband was a carrier of a novel RB1 constitutive mutation (g.2056C>G) which was not detected in her father or her unaffected sisters, and of two other mutations (g.39606 C>T and g.174351T>A) also present in two monozygotic sisters. The novel mutation probably occurred de novo while the others were of likely maternal origin. The novel mutation, affecting the Kozak consensus at the 5'UTR of RB1 and g.174351T>A were likely associated to retinoblastoma in the proband.
Molecular diagnosis of retinoblastoma requires genotypic data of the family for determining hereditary transmission. In the case of children generated by IVF with oocytes from an anonymous donor which had been stored in a cell repository, this might not be successfully accomplished, making precise diagnosis impracticable for genetic counseling.
Retinoblastoma (RB; MIM #180200) is the most common intraocular pediatric tumor, with an incidence of 1/15,000–25,000 live births. It results from mutational inactivation of both alleles of the tumor suppressor RB1 gene that encodes a nuclear phosphoprotein (pRB) involved in the control cell cycle [1–3]. In the hereditary form, accounting for 40% of RB patients, an RB1 germline mutation is transmitted as an autosomal dominant trait with high penetrance (90%), resulting in a 45% risk of occurrence in the offspring, with increased risk for secondary malignancies. In the sporadic form, mutational inactivation of both RB1 alleles arises from somatic events in retinal cells, without germline alterations .
Genetic alterations frequently resulting from RB1 inactivation involve chromosome rearrangements affecting the 13q14 region (deletion, translocation), nucleotide changes (substitutions, deletions, insertions and duplications), exonic deletions (single or multiple); loss of heterozygosity , or CpG island hypermethylation of the RB1 promoter region . Epigenetic mechanisms playing a role in some RB patients include differential methylation of chromosome 13q around RB1  and preferential loss of maternal alleles in sporadic cases, suggesting a latent imprinting .
Identification of RB1 mutations in hereditary RB provides accurate risk prediction and valuable genetic counseling for patients and their families. Furthermore, the nature of a mutation can determine genetic penetrance, disease presentation and prognosis .
Recent investigations suggest an apparent association between in vitro fertilization (IVF) and genetic syndromes, including retinoblastoma . It has been postulated that embryos in culture may acquire epigenetic defects as a result of abnormal environmental conditions which may lead to aberrant phenotypes. These studies illustrated a complex problem involving legal and ethical aspects and privacy protection in the field of assisted reproductive technologies (ART), with potential implications in the genetic counseling of retinoblastoma.
We herein describe a novel constitutive mutation at the 5' UTR of RB1 in a patient with bilateral retinoblastoma, who also carried two other constitutive mutations also present in two of her sisters conceived by IVF.
Patients and samples
We studied a family of female quadruplets (A, B, C and D) conceived by IVF of oocytes from one anonymous donor with sperm of their father. One quadruplet presented bilateral retinoblastoma diagnosed by current ophthalmological and histopathological criteria at one month of age. The proband (A) was referred to the Genetic Counseling Program of the Instituto Nacional de Cancer (Rio de Janeiro, Brazil) and subsequently selected for mutational screening, together with her three sisters and their father. All quadruplets have been followed by periodical ophthalmological examinations to present.
Blood samples were obtained from the quadruplets and their father. Samples and information on the family were obtained with an informed consent. Tumor samples were not available for analysis. With respect to privacy and anonymity required for IVF, blood samples could not be obtained from the female donor. This study was approved by local Ethics Committee and followed the tenents and guidelines of the Declaration of Helsinki.
RB1 exons 2–27 were PCR-amplified in individual reactions containing 100 ng DNA, 0.4 pm of each primer [forward and reverse previously reported ], 0.15 mM of each dNTP, 3 mM MgCl2, 1× PCR buffer (Promega Corporation, Madison, Wisconsin, USA) and 1 U of Taq DNA polymerase (Promega Corporation) in 50 μl reactions. PCR was performed with 40 cycles at 94°C (1 min), 54°C (40 sec) and 72°C (35 sec) in a programmable thermocycler (PT-100; MJ Research, Inc., Waltham, Massachussets, USA). Reaction mixes were prepared as previously described , with Taq DNA Polymerase, Recombinant (Invitrogen, Carlsbad, California, USA). PCR conditions were 40 cycles at 94°C (1 min), 49°C (40 sec) and 72°C (35 sec), in a programmable thermocycler (PT-100; MJ Research, Inc.).
RB1promoter region and exon 1 analysis
Forward 5'-GGTTTTTCTCAGGGGACGTT-3' and reverse 5'-AACCCAGAATCCTGTCACCA-3' primers were used to amplify the RB1 promoter and exon 1 from genomic DNA. Reaction mixes were prepared containing 100 ng DNA, 0.4 pm of each primer (forward and reverse), 5% DMSO, 0.15 mM of each dNTP, 3 mM MgCl2, 1× PCR buffer (Promega Corporation, Madison, Wisconsin, USA) and 1 U of Platinum Taq DNA polymerase (Promega Corporation) in 50 μl reactions. PCR was performed with 40 cycles at 94°C (1 min), 50°C (40 sec) and 72°C (45 sec) in a programmable thermocycler (PT-100; MJ Research, Inc., Waltham, Massachussets, USA).
RNA was extracted from blood cells of the proband isolated with Ficoll-Paque PLUS® (GE Healthcare UK, Little Chalfont, UK) using TRIZOL® (Invitrogen Corporation, California, USA) following the specifications of the manufacturer and cDNA was synthesized with SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen Corporation, California, USA).
A cDNA region, including part of the 5' UTR of RB1, was amplified using the forward primer 5'-CTCCCCGGCGCTCCTCCACAGC-3' annealing downstream of transcription start sites -176 and -128  and the reverse primer 5'-AGAACACCACGAAAAAGTAA-3' annealing in exon 6. Reaction mixes contained 100 ng cDNA, 0.4 pm of each primer, 5% DMSO, 0.15 mM of each dNTP, 3 mM MgCl2, 1× PCR buffer (Promega Corporation, Madison, Wisconsin, USA) and 1 U of Platinum Taq DNA polymerase (Promega Corporation) in 50 μl reactions. PCR was performed with 50 cycles at 94°C (1 min), 55°C (40 sec) and 72°C (1 min) in a programmable thermocycler (PT-100; MJ Research, Inc., Waltham, Massachussets, USA).
Amplified products were electrophoresed in 2% agarose gels with ethidium bromide. Direct sequencing was performed with an ABI PRISM 377 automatic DNA sequencer (Applied Biosystems, Foster City, California, USA). Sequences were analyzed using Sequencher TM Demo Version 4.1.4 software (Gene Codes Corporation 2005 – 775 Technology Drive, Ann Arbor, Michigan, USA) and compared to a reference sequence (Genbank accession L11910.1). Constitutive alterations identified in this study were compared with those published in RB1 gene mutation database-Retinoblastoma Genetics website (available at http://www.verandi.de/joomla/index.php).
Diagnosis of zygosity
Genotyping was carried out with PowerPlexTM16 System (Promega Corporation), following the recommendations of the manufacturer, for identifying quadruplet zygosity. This assay comprised multiplex PCR amplifications of 15 STR loci, including D13S317 (a microsatellite marker located at 13q22-q31). An additional microsatellite flankling RB1 (D13S284 located at 13q14.3) was also used for genotyping.
Genotyping of four quadruplets and father.
Deduced maternal alleles
31 – ?
14? – or 15?
5 – ?
9 – ?
13 – ?
11 – ?
Genotyping of quadruplets and father with respect to mutations and 13q markers.
g.2056C>G (in – 4 position in 5'UTR)
g.39606C>T (in intron 3)
g.174351T>A (in intron 25)
Several clinical reports have suggested an association between assisted reproduction technologies (ART) and increased risk of genetic disorders including retinoblastoma, in children conceived with the use of ART. These might be a consequence of accumulation of epigenetic alterations during embryo culture and/or alteration of developmental timing. In some cases of retinoblastoma, RB1 was epigenetically silenced by hypermethylation at the promoter region, resulting in reduced RB1 expression. Since tumor material was not available, peripheral assessment of methylation of the RB1 promoter in leukocytes would not have been informative because the dynamics of DNA methylation in primary tumor tissues are clearly different from normal cells, and not confined to specific CpG sites .
RB1patterns and haplotypes
Genotypic analysis of 13q was carried out with three intragenic RB1 alleles and two microsatellites closely linked to RB1. Presumably, transmission of intragenic alleles occurred without recombination, corresponding to parental RB1 patterns [C-C-T] and [C-T-A]. Conversely, the possibility of recombination might have occurred between RB1, D13S284 and D13S317.
The putative paternal haplotypes were [C-C-T]-213-11 and [C-C-T]-215-12, and the likely maternal haplotypes were [C-T-A]-213-9 and [C-C-T]-205-9. The mother could be a 9/9 homozygous for D13S317 or, alternatively, [C-C-T]-205-9 was a recombinant haplotype, in view that 213-9 cosegregation was more frequent than 205-9.
Parental origin of mutations
The father was found to be a C/C homozygote at g.2056, while genotypic data indicated that the mother was also a C/C homozygote. Thus, g.2056C>G was not constitutional in the proband's progenitors and could have occurred either in the maternal or the paternal RB1 allele, as a de novo event in germ lines or in the zygote.
Alternatively, haplotypic data indicated that g.2056C>G could have occurred in the maternal RB1 allele because the expected paternal haplotype was [C-C-T]-213-11 and the expected maternal haplotype was [C-T-A]-213-9. A putative paternal haplotype, identical with the expected one, could be deduced in the proband, together with a putative maternal [G-T-A]-213-9 haplotype derived from the expected maternal haplotype.
Genotypic analysis indicated that both g.39606T and g.174351A alleles were of maternal origin because they were not present in the father. They were present in three quadruplets derived from two different embryos (A, C and D). Moreover, in the proband, in whom the paternal haplotype [C-C-T]-213-11 was deduced, these two mutations must have co-segregated with the maternal 213-9 alleles as was the case of quadruplets C and D. Moreover, the fact that child B did not carry these alleles ruled out the possibility of co-segregation with the paternal alleles 215-12 in B, C and D (Table 2).
Association of mutations with retinoblastoma
We identified a novel constitutive mutation in the 5' UTR of the RB1 promoter region (g.2056C>G), in position – 4 with respect to the initial translation ATG codon in an infant, born after IVF, and affected with bilateral retinoblastoma. Mutations that weaken adherence to the Kozak consensus sequence in the 5'UTR have been found to negatively affect translation initiation. In eukaryotes, sequences flanking the AUG codon modulate their ability to halt scanning of the 40S ribosomal subunit and to initiate translation . Translational efficiency was not herein analyzed, but Cs in these positions are highly conserved, being part of the consensus reference. This was confirmed by extensive analysis of Genbank data from 5'UTR sequences of some 700 vertebrate mRNAs . Tumor samples were not available for analysis, a reason why studies of RB1 expression were not carried out with this material. cDNA analysis of blood RNA of the proband, however, indicated that only the g.2056C allele, in position -4 and located in the 5' UTR of RB1, was expressed, with an apparent null expression of the g.2056G allele.
Mutations detected in intron 3 (g.39606C>T) and intron 25 (g.174351T>A) in the proband and her two sisters (C and D) are less likely to be associated to retinoblastoma than g.2056C>G. The g.39606C>T mutation has been considered to be polymorphic  while g.174351T>A was also present as a polymorphic trait in unaffected individuals, with a frequency of 0.70 for the g.174351T allele and 0.30 for the g.174351A allele . Conversely, g.174351T>A was associated to bilateral retinoblastoma in one patient in whom this mutation was constitutional and the only alteration to which retinoblastoma could be associated . Interestingly, we also found this mutation as the only alteration in seven patients with retinoblastoma (Barbosa et al., unpublished data), a finding suggesting that g.174351T>A might be associated to development of retinoblastoma. Furthermore, the fact that g.174351T>A was also found in the unaffected quadruplets C and D does not exclude the possibility of retinoblastoma at older age.
Genetic counseling and in vitrofertilization
In this study, retinoblastoma was detected in the proband at one month of age, a reason why the possibility of tumor development could not be excluded in her sisters. This is especially relevant for the monozygotic infants C and D who carried g.39606C>T and g.174351T>A and who must be followed by serial fundoscopic analyses. These mutations might be associated to retinoblastoma in view of previous reports and our unpublished observations.
With respect to IVF, the direct physical manipulation of gametes and embryos in the ex vivo environment might result in the appearance de novo point mutations resulting in the majority of genetic diseases in humans. Moreover, in a study of mouse embryos showed that genetic alterations in culture conditions might have considerable impact on the quality of embryos derived by ART .
These results have implications for genetic counseling. Recurrent transmissions or potential transmissions of Mendelian disorders through the same gamete donor have been reported in ART - and constitutive RB1 mutations may appear de novo or be transmitted by one progenitor . For establishing an accurate molecular diagnosis of retinoblastoma, genotypic data are necessary, mainly for distinguishing between hereditary from sporadic retinoblastoma. In this case, in which blood samples from the oocyte donor was not available, hereditary retinoblastoma could not be proven.
In ART, occurrence or risk of occurrence of a genetic disorder in the family must be calculated. Medical, family and reproductive histories of female and male donors must be obtained, and appropriate genetic counseling should be offered and genetic testing implemented . These requirements cannot be met if the anonymity of gamete donors were to be respected with all ethical, legal, and psychological implications, thus making impracticable a precise diagnosis for genetic counseling. Our finding requires further research to confirm the association between IVF and retinoblastoma and to explore likely causal mechanisms.
We are grateful to Rodrigo Soares de Moura Neto for helping us with genotyping and to Anna Claudia Evangelista dos Santos for helping us with blood collections. Work supported by SWISSBRIDGE FOUNDATION (Switzerland), FAPERJ grant E/26 110.944/2008 and CNPq grant 400811/05-7. RH Barbosa is a recipient of a PhD scholarship from CAPES (Brazilian Coordination for the Improvement of Higher Education Personnel).
- Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, Murphree AL, Strong LC, White RL: Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature. 1983, 305 (5937): 779-784. 10.1038/305779a0.View ArticlePubMedGoogle Scholar
- Kaelin WG: Functions of the retinoblastoma protein. Bioessays. 1999, 21 (11): 950-958. 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D.View ArticlePubMedGoogle Scholar
- Cavenee WK: Chromosomal mechanisms in the initiation of human familial mixed cancers. Princess Takamatsu Symp. 1986, 17: 171-179.PubMedGoogle Scholar
- Lee V, Hungerford JL, Bunce C, Ahmed F, Kingston JE, Plowman PN: Globe conserving treatment of the only eye in bilateral retinoblastoma. Br J Ophthalmol. 2003, 87 (11): 1374-1380. 10.1136/bjo.87.11.1374.View ArticlePubMedPubMed CentralGoogle Scholar
- de Andrade AF, da Hora Barbosa R, Vargas FR, Ferman S, Eisenberg AL, Fernandes L, Bonvicino CR: A molecular study of first and second RB1 mutational hits in retinoblastoma patients. Cancer Genet Cytogenet. 2006, 167 (1): 43-46. 10.1016/j.cancergencyto.2005.08.017.View ArticlePubMedGoogle Scholar
- Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP: Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet. 1991, 48 (5): 880-888.PubMedPubMed CentralGoogle Scholar
- Blanquet V, Turleau C, Gross MS, Goossens M, Besmond C: Identification of germline mutations in the RB1 gene by denaturant gradient gel electrophoresis and polymerase chain reaction direct sequencing. Hum Mol Genet. 1993, 2 (7): 975-979. 10.1093/hmg/2.7.975.View ArticlePubMedGoogle Scholar
- Niemitz EL, Feinberg AP: Epigenetics and assisted reproductive technology: a call for investigation. Am J Hum Genet. 2004, 74 (4): 599-609. 10.1086/382897.View ArticlePubMedPubMed CentralGoogle Scholar
- Lohmann DR, Gerick M, Brandt B, Oelschlager U, Lorenz B, Passarge E, Horsthemke B: Constitutional RB1-gene mutations in patients with isolated unilateral retinoblastoma. Am J Hum Genet. 1997, 61 (2): 282-294. 10.1086/514845.View ArticlePubMedPubMed CentralGoogle Scholar
- Gill RM, Hamel PA, Zhe J, Zacksenhaus E, Gallie BL, Phillips RA: Characterization of the human RB1 promoter and of elements involved in transcriptional regulation. Cell Growth Differ. 1994, 5 (5): 467-474.PubMedGoogle Scholar
- Kiran VS, Kannabiran C, Chakravarthi K, Vemuganti GK, Honavar SG: Mutational screening of the RB1 gene in Indian patients with retinoblastoma reveals eight novel and several recurrent mutations. Hum Mutat. 2003, 22 (4): 339-10.1002/humu.9181.View ArticlePubMedGoogle Scholar
- Nichols KE, Houseknecht MD, Godmilow L, Bunin G, Shields C, Meadows A, Ganguly A: Sensitive multistep clinical molecular screening of 180 unrelated individuals with retinoblastoma detects 36 novel mutations in the RB1 gene. Hum Mutat. 2005, 25 (6): 566-574. 10.1002/humu.20184.View ArticlePubMedGoogle Scholar
- Stirzaker C, Millar DS, Paul CL, Warnecke PM, Harrison J, Vincent PC, Frommer M, Clark SJ: Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. Cancer Res. 1997, 57 (11): 2229-2237.PubMedGoogle Scholar
- Kozak M: Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell. 1986, 44 (2): 283-292. 10.1016/0092-8674(86)90762-2.View ArticlePubMedGoogle Scholar
- Kozak M: An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. 1987, 15 (20): 8125-8148. 10.1093/nar/15.20.8125.View ArticlePubMedPubMed CentralGoogle Scholar
- Bean CJ, Hassold TJ, Judis L, Hunt PA: Fertilization in vitro increases non-disjunction during early cleavage divisions in a mouse model system. Hum Reprod. 2002, 17 (9): 2362-2367. 10.1093/humrep/17.9.2362.View ArticlePubMedGoogle Scholar
- Burns WN, Schiaffino MV, Lewis RA: Repeated transmission of X-linked ocular albinism type 1 by a carrier oocyte donor. Fertil Steril. 1998, 70 (6): 1169-1172. 10.1016/S0015-0282(98)00387-2.View ArticlePubMedGoogle Scholar
- Tizzano EF, Cusco I, Barcelo MJ, Parra J, Baiget M: Should gamete donors be tested for spinal muscular atrophy?. Fertil Steril. 2002, 77 (2): 409-411. 10.1016/S0015-0282(01)02994-6.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/10/75/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.